Sjogren’s Syndrome Beyond Sicca – A Case Series of Four Cases with an Overview of Varied Neurological Manifestations Authors: Saravana Sukriya, S Madhumitha, AS Girish, Sabah Siddiqui, Joydeep Samanta, Manish Kumar, P Aruna Published: 2026 Dear Editor, Sjogren’s syndrome (SS) is a heterogeneous autoimmune disease characterized by lymphocytic infiltration and chronic inflammation of the lacrimal and salivary glands, resulting in the classical sicca symptoms. The diagnosis of SS is based on the 2016 American College of Rheumatology and European League against Rheumatism (ACR/EULAR) classification criteria, which comprises five key components - objective evidence of dry eyes (Schirmer’s test and abnormal ocular staining score), evidence of dry mouth, presence of antibodies against anti-Ro/anti-SSA, focal lymphocytic sialadenitis detected by labial salivary gland biopsy, with a focus score >1 – an aggregation of >50 lymphocytes per 4 mm2 salivary gland.[1] Besides the glandular involvement, the disease is notorious for its multifaceted systemic involvement, including the nervous system. We report four cases of neuro-Sjogren’s syndrome, highlighting the diverse clinical manifestations and disease management. Case 1: A middle-aged female presented with complaints of one episode of generalized tonic–clonic seizures 4 months back, acute-onset of right hemiparesis with dysarthria 3 months back, followed by gradually progressive cognitive decline. Her medical history revealed hypothyroidism and frequent hospitalizations in view of flaccid quadriparesis, which improved with potassium supplementation. On examination, she was conscious, was easily distractible, could recall her name, yet was disoriented to time, place and person. A mini mental state examination (MMSE) revealed a score of 8/30. Investigations revealed serum potassium 2.8 mEq/L (normal 3.5–4.5) and non-anion gap metabolic acidosis on blood gas analysis. Magnetic resonance imaging (MRI) of the brain revealed chronic infarcts in left parietal and right cerebellar regions, periventricular microangiopathic changes, and cerebral atrophy [Figure 1]. Angiogram revealed contrast enhancement of bilateral internal carotid arteries and diffuse narrowing of anterior, middle, and posterior cerebral arteries, suggestive of vasculitis [Figure 1]. Antinuclear antibodies (ANA) by immunofluorescence was positive (speckled pattern) with immunoblot showing strong, positive anti-Ro/anti-SSA and positive anti-La/anti-SSB. A possibility of neuro-Sjogren’s syndrome was considered, and she was started on intravenous pulse methylprednisolone and rituximab. At 3-month follow-up, she showed significant improvement in her cognitive assessment, with a score of 25/30 in MMSE. (a) T1-weighted MRI brain showing hypointensity in the left frontal lobe suggestive of chronic infarct. (b) T2-FLAIR-weighted MRI brain showing hyperintensity in the left frontal lobe suggestive of chronic infarct. (c) MR angiogram showing diffuse narrowing of the anterior, middle, and posterior cerebral arteries (arrows). (d) Vessel wall imaging showing diffuse homogenous enhancement along the bilateral internal carotid arteries (arrow). MRI: Magnetic resonance imaging, FLAIR: Fluid-attenuated inversion recovery, MR: Magnetic resonance. The central nervous system involvement in SS is characterized by involvement of the spinal cord, optic nerves, and cerebral and cerebellar hemispheres, presenting as transverse myelitis, optic neuritis, multiple sclerosis-like white matter disease, seizures, ataxia, and cognitive decline. The presence of contrast enhancement along the vessel wall with stenosis of the anterior, posterior, and middle cerebral arteries in the background of stroke-like episodes, seizures, and cognitive decline favored a diagnosis of central nervous system (CNS) vasculitis. The absence of collaterals ruled out the possibility of moyamoya disease, and the absence of eccentric wall enhancement ruled out the possibility of intracranial atherosclerosis in our patient. The pathogenesis of vasculitis involves immune complex deposition, complement activation, neutrophil chemotaxis, endothelial damage, fibrinoid necrosis, and vessel occlusion. CNS vasculitis affecting small vessels is commonly reported in SS.[2] However, involvement of medium and large vessels, as in our case, is quite rare in neuro-Sjogren’s syndrome.[3] Hypokalemia often occurs in SS due to renal tubular dysfunction. The chronic interstitial nephritis results in decreased tubular sodium delivery, secondary hyperaldosteronism, bicarbonaturia resulting in renal tubular acidosis, and recurrent hypokalemia.[4] Case 2: A young female was admitted with a 2-month history of gradually progressive quadriparesis associated with paresthesia of bilateral hands and feet, dysphagia, and dysarthria. She had recurrent episodes of dizziness followed by syncope on getting up from the supine position. On examination, she had bilateral facial and bulbar weakness and flaccid quadriparesis with orthostatic hypotension. Nerve conduction study revealed demyelinating sensorimotor polyradiculoneuropathy. MRI of the brain and spine was unremarkable. Cerebrospinal fluid (CSF) routine examination showed albuminocytological dissociation, with negative infectious and atypical cells. ANA by immunofluorescence showed speckled pattern, and immunoblot revealed strong positivity for anti-Ro/anti-SSA and anti-La/anti-SSB antibodies. The Schirmer test revealed severe dry eyes. Lip biopsy showed chronic sialadenitis with a focus score >1 [Figure 2]. Diagnosis of neuro-Sjogren’s syndrome with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) was considered, and she was started on pulse i.v. methylprednisolone followed by rituximab. (a) Low-power view of the salivary gland showing periductal lymphocyte infiltrate with lymphoid aggregates and fibrosis (arrow). (b) Lymphocyte infiltrate with acinar atrophy (arrow). Peripheral neuropathy predates the diagnosis of SS in approximately 90% cases,[5] with 30% cases preceding the typical sicca symptoms.[6] The spectrum of peripheral neuropathy in SS includes ganglionopathy, trigeminal neuropathy, polyradiculoneuropathies, cranial neuropathy, pure sensory neuropathy, and mononeuropathies. Sensory predominant peripheral neuropathy often warrants a workup for SS. Polyradiculoneuropathies are far less common in neuro-Sjogren’s syndrome. Dysautonomia is seen in around 50% of patients with SS,[5] and it usually co-occurs with peripheral neuropathy. The presence of dysautonomia and cranial nerve palsies with flaccid quadriparesis favored the diagnosis of CIDP. A study comparing patients with CIDP associated with SS and CIDP without SS[7] observed that female gender and cranial nerve involvement are two independent red flags for patients with CIDP associated with SS. Case 3: A young female presented with sicca symptoms and a 4-week history of gradually progressive ataxia. Neurological examination revealed normal cognition with scanning speech, sluggish deep tendon reflexes, mute plantar and features of cerebellar ataxia. Thyroid function, serum vitamin B12, and ceruloplasmin levels were normal. MRI brain showed diffuse cerebellar atrophy [Figure 3]. Routine CSF analysis was unremarkable, and CSF oligoclonal bands, autoimmune, para-neoplastic, and spinocerebellar ataxia panels were normal. ANA immunoblot revealed strong positive anti-Ro/anti-SSA antibodies. A labial biopsy was done, which showed focal lymphocytic sialadenitis with a focus score >1. A diagnosis of cerebellar ataxia secondary to SS was considered, and the patient was started on intravenous pulse methylprednisolone followed by rituximab. At 1-year follow-up, she could stand and walk with minimal support. (a) T2-weighted MRI brain showing prominent cerebellar folia and fourth ventricle suggestive of diffuse cerebellar atrophy. (b) T1-weighted contrast-enhanced MRI brain showing no obvious contrast enhancement of the cerebellum. (c) T2-FLAIR-weighted MRI brain showing no periventricular hyperintensities suggestive of ischemia. MRI: Magnetic resonance imaging, FLAIR: Fluid-attenuated inversion recovery. Cerebellar ataxia in SS is mediated by antineuronal antibodies against Purkinje cells and vasculitis, resulting in microinfarcts and cerebellar atrophy.[8] The absence of microangiopathic changes in the MRI brain [Figure 3] in this case ruled out the possibility of vasculitis causing cerebellar degeneration. Cerebellar ataxia is uncommon in SS with a variable prognosis.[9] Case 4: A middle-aged female, with no prior comorbidities, presented with 1-month history of progressive quadriparesis, dysphagia, and dysarthria. She denied any fluctuations or diurnal variation of symptoms. She also complained of dry mouth. On examination, she had sluggish palatal movements, with absent gag reflex, neck drop, and hypotonia on all four limbs. The Medical Research Council power grading was 2/5 in bilateral shoulders and hips, 3/5 in bilateral elbows and knees, and 4+/5 in bilateral wrists and ankles. Deep tendon reflexes were present with bilateral flexor plantar responses. Sensory examination was unremarkable. On evaluation, hemogram, renal and liver function assays, and muscle enzymes were within normal limits. Nerve conduction studies did not reveal any abnormality. ANA immunofluorescence showed a cytoplasmic speckled pattern, and the immunoblot profile was positive for anti-La/anti-SSB antibodies, and strong, positive for anti-Ro/anti-SSA antibodies. A muscle biopsy from the left deltoid was performed, which revealed features of an inflammatory necrotizing myopathy [Figure 4]. Myoblot showed positive anti-SRP antibodies and strong positive anti-Ro/anti-SSA antibodies. A possibility of SS and immune-mediated necrotizing myositis (SS-IMNM) was considered. She received intravenous immunoglobulin at 2 g/kg over 5 days and intravenous pulse methylprednisolone (1 g/day for 5 days) followed by oral steroids. She was also started on rituximab and mycophenolate mofetil. The scanner view (4X, a) and low-power view (10x, b) images of H and E-stained muscle biopsy showing mild variation in fiber size, patchy inflammation (arrows), lymphocyte infiltrate, and necrosis in the endomysium. H and E: Hematoxylin and eosin. The co-existence of SS and anti-SRP antibody-positive IMNM is infrequently reported.[10] The clinical course of SS-IMNM overlap is highly variable, ranging from mild muscle weakness with slow progression to severe weakness with rapid deterioration. The response to immune modulation varies significantly, with some patients experiencing improvement, whereas others fail to show any response.[1112] Apart from muscular involvement, anti-SRP antibody-associated IMNM is characterized by severe extra-muscular manifestations, including interstitial lung disease and cutaneous manifestations.[13] The treatment of SS includes symptomatic management of sicca symptoms with muscarinic agonists and immunomodulation therapy. The conventional synthetic disease-modifying antirheumatic drugs, including hydroxychloroquine, sulfasalazine and methotrexate, and biologic agents targeting B-cells, T-cells, and cytokines are effective in controlling symptoms and improving patient outcomes. Severe organ-threatening manifestations warrant treatment with high-dose corticosteroids and immunosuppression with cyclophosphamide or rituximab.[14] A systematic review and meta-analysis on the role of rituximab in the treatment of SS showed that early initiation of rituximab therapy was associated with a significant reduction in disease activity.[15] The neurological complications of SS often predate the typical glandular manifestations of SS by years. In the context of unexplained peripheral neuropathy, the clinician should maintain a high index of suspicion for SS. A lip biopsy, antibody testing and radiological assessment can aid in timely diagnosis and appropriate treatment. The limitations of our study include a small sample size and variable follow-up. Future multicenter studies with larger cohorts are required to understand the heterogeneity of disease manifestations and explore effective therapeutic options in neuro-Sjogren syndrome. Declaration of patient consent The authors certify that they have obtained all appropriate patient consent forms. In the form, the patients have given their consent for their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and that due efforts will be made to conceal their identity, but anonymity cannot be guaranteed. Conflicts of interest There are no conflicts of interest.